Ranibizumab 0.3 mg for Persistent Diabetic Macular Edema After Recent, Frequent, and Chronic Bevacizumab: The ROTATE Trial

Abstract

Ranibizumab 0.3 mg demonstrated improved visual and anatomic outcomes in patients with persistent DME following bevacizumab. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:1030-1037.].

Kostenvergleich zugelassener intravitrealer Therapien bei nicht ausreichend auf primäre Therapie ansprechendem diabetischem Makulaödem mit fovealer Beteiligung in Deutschland

“…Derzeit liegen erste Studien niedrigerer Evidenzstufen zur Effektivität einer Therapie nach vorangegangener Anti-VEGF-Therapie vor [8 -14], die jedoch noch kein eindeutiges Bild erlauben. Eine Vorbehandlung mit Anti-VEGF scheint jedoch wenig Einfluss auf die Effektivität zu haben [28,29]. Bei nicht vorbehandelten Patienten scheint Aflibercept gegenüber Ranibizumab und Bevacizumab bei bestimmten Patientengruppen eine höhere Effektivität zu haben [6].…”

Use of Corticosteroids in the Treatment of Patients With Diabetic Macular Edema Who Have a Suboptimal Response to Anti-VEGF: Recommendations of an Expert Panel

“…23 After 2 years of treatment, aflibercept and ranibizumab provided similar improvement in BCVA, and aflibercept continued to be more effective than bevacizumab in improving BCVA in patients with baseline BCVA worse than 20/40. 24 Although the efficacy of switching among anti-VEGF therapies has not been well studied, 25 favorable outcomes have been reported after patients with suboptimal response switched from bevacizumab to ranibizumab, 26 or from bevacizumab or ranibizumab to aflibercept. 27 Therefore, if a patient has a poor early response to anti-VEGF, and the initial anti-VEGF agent used was not aflibercept because of considerations such as cost and reimbursement, the clinician may consider switching the patient to aflibercept.…”

Diabetic Macular Edema Patients with Poor Baseline Visual Acuity Treated with Ranibizumab in Real Life and Optical Coherence Tomography Based Predictor Factors for Visual Outcomes

“…Diabetic retinopathy (DR) is the most frequent retinal vascular disease and diabetic macular edema (DME) is an important cause of visual loss among the DR patients (1)(2)(3)(4)(5).…”

“…Laser photocoagulation, vitrectomy, and intravitreal injections of different drugs were used in the treatment of DME (2)(3)(4)(5). Intravitreal injection of anti-vascular endothelial growth (Anti-VEGF) agents is the most preferred treatment modality currently (4)(5)(6)(7)(8)(9).…”